Lovenox/Enoxaparin Antitrust Settlement

Settlement Structure: Claims Made

Active: Closed

Closed Settlement Statement:

According to court documents, the claim submission deadline has passed. Please contact the claims administrator if you have any questions.

Case Summary:

Momenta Pharmaceuticals, Inc. and Sandoz, Inc. are settling an antitrust class action alleging that they conspired to keep the prices of Lovenox and its generic enoxaparin higher than they should have been by manipulating the generic approvals process. While Momenta did not create the drug, the complaint says the companies manipulated the process to bring testing processes for generics within the scope of Momenta’s patents. Thus it allegedly wanted to require other companies to use or infringe on its patented processes, in order to keep other drug makers from selling it.

Docket Number:


Company: Momenta Pharmaceuticals Inc.

Filing Deadline: July 3, 2020

Class Period: September 21, 2011 to September 30, 2015

Objection Deadline: March 16, 2020

Final Approval Hearing: May 29, 2020

Proof of Purchase:

Uninsured individuals may not have to provide documentation, but other class members must.


You may be eligible if you meet the following criteria:

  • You are a hospital, third-party payor, or a person without insurance who indirectly bought, paid for, or reimbursed some or all of the price for Lovenox or enoxaparin,
  • In Arizona, Arkansas, California, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin,
  • Between September 21, 2011 and September 30, 2015, 
  • For personal consumption by yourself or your family, or your members, employees, insureds, participants, patients, beneficiaries, or anyone else.
Typical Settlement Amount:

Recoveries will be based on how much each class member paid for the drugs during the class period compared to the amount paid by other class members. Different calculations may be made for hospitals, third-party payors, and uninsured individuals. For more information, see the Distribution Plan at https://www.dvtmedslawsuit.com/docs/Proposed%20Distribution%20Plan%20dated%2012-20-19.pdf.

Total Settlement Amount: $120 million

Class Representative Proposed Incentive Fee:

Up to $200,000

Law Firm:
Lieff Cabraser Heimann & Bernstein

Claim Form: Lovenox/Enoxaparin Antitrust Settlement Claim Forms

Case Name: The Hospital Authority of Metropolitan Government of Nashville and Davidson County v. Momenta Pharmaceuticals, Inc.

Settlement Website: Lovenox/Enoxaparin Antitrust Settlement Website

Claims Administrator:
AB Data, Ltd.

Claims Administrator Contact Information:

Enoxaparin Antitrust Settlement
c/o A.B. Data Ltd.
P.O. Box 173090
Milwaukee, WI 53217

Tags: Antitrust, Drugs and Generics, Pharmaceuticals